|

Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant

RECRUITINGN/ASponsored by Institute of Liver and Biliary Sciences, India
Actively Recruiting
PhaseN/A
SponsorInstitute of Liver and Biliary Sciences, India
Started2024-12-01
Est. completion2025-12-10
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06743464

Summary

Liver transplantation has been a lifesaving treatment for individuals with end stage liver disease and acute liver failure. However, initial poor function of a liver allograft after liver transplantation, termed early graft dysfunction (EGD), has been associated with increased allograft loss or mortality after transplantation. EGD in LDLT is multifactorial. Factors affecting EGD are GRWR, ischemia reperfusion injury, recipient metabolic demand, graft quality, graft inflow and outflow. Studies shows that the incidence of EGD is 15-38%. It is associated with increased allograft loss \& mortality. Rifaximin is an antibiotic that reduces EGD by 50% as shown by 2 studies but this study was done in DDLT setting and rifaximin was given in the pretransplant group. In this investigators will study the effect of perioperative oral rifaximin on early graft dysfunction in adult living donor liver transplant.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* All recipients (adults) undergoing living donor liver transplant in ILBS.

Exclusion Criteria:

* Negative consent

  * Hypersensitivity to Rifaximin
  * Patients undergoing retransplant
  * ALF, ACLF
  * Pediatrics patients
  * Patients on rifaximin

Conditions2

Chronic Liver DiseaseLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.